{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:21:24Z","timestamp":1788402084457,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2021\/05\/X\/NZ7\/00353"],"award-info":[{"award-number":["2021\/05\/X\/NZ7\/00353"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00467-025-07144-y","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:53:23Z","timestamp":1769180003000},"page":"1705-1719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Plasma-saliva correlations for total and unbound mycophenolic acid and its glucuronide in children with nephrotic syndrome"],"prefix":"10.1007","volume":"41","author":[{"given":"Klaudia","family":"Babacz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Benedyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Zachwieja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Ostalska-Nowicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-1575","authenticated-orcid":false,"given":"Joanna","family":"Sobiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"7144_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106970","volume":"204","author":"J Saito","year":"2025","unstructured":"Saito J, Yamatani A, Akabane M et al (2025) Population pharmacokinetic analysis in children with different diseases treated with mycophenolate mofetil\u2014integrated analysis of clinical trials and real-world clinical data. Eur J Pharm Sci 204:106970. https:\/\/doi.org\/10.1016\/j.ejps.2024.106970","journal-title":"Eur J Pharm Sci"},{"key":"7144_CR2","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/bcp.14590","volume":"87","author":"Y Rong","year":"2021","unstructured":"Rong Y, Jun H, Kiang TKL (2021) Population pharmacokinetics of mycophenolic acid in paediatric patients. Br J Clin Pharmacol 87:1730\u20131757. https:\/\/doi.org\/10.1111\/bcp.14590","journal-title":"Br J Clin Pharmacol"},{"key":"7144_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17425255.2021.1843633","volume":"17","author":"R Ehren","year":"2021","unstructured":"Ehren R, Schijvens AM, Hackl A et al (2021) Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. Expert Opin Drug Metab Toxicol 17:201\u2013213. https:\/\/doi.org\/10.1080\/17425255.2021.1843633","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"7144_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70092","volume":"18","author":"P Zheng","year":"2025","unstructured":"Zheng P, Pan T, Gao Y et al (2025) Predicting the exposure of mycophenolic acid in children with autoimmune diseases using a limited sampling strategy: a retrospective study. Clin Transl Sci 18:e70092. https:\/\/doi.org\/10.1111\/cts.70092","journal-title":"Clin Transl Sci"},{"key":"7144_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00467-023-05974-2","volume":"39","author":"FF Lai","year":"2024","unstructured":"Lai FF, Chan EY, Tullus K, Ma AL (2024) Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review. Pediatr Nephrol 39:85\u2013103. https:\/\/doi.org\/10.1007\/s00467-023-05974-2","journal-title":"Pediatr Nephrol"},{"key":"7144_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00467-015-3303-3","volume":"31","author":"EC Yoo","year":"2016","unstructured":"Yoo EC, Alvarez-El\u00edas AC, Todorova EK, Filler G (2016) Developmental changes of MPA exposure in children. Pediatr Nephrol 31:975\u2013982. https:\/\/doi.org\/10.1007\/s00467-015-3303-3","journal-title":"Pediatr Nephrol"},{"key":"7144_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","volume":"77","author":"J Sobiak","year":"2015","unstructured":"Sobiak J, Resztak M, Ostalska-Nowicka D et al (2015) Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci 77:189\u2013196. https:\/\/doi.org\/10.1016\/j.ejps.2015.06.017","journal-title":"Eur J Pharm Sci"},{"key":"7144_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E et al (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3","journal-title":"Pediatr Nephrol"},{"key":"7144_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/bios13020206","volume":"13","author":"H Min","year":"2023","unstructured":"Min H, Zhu S, Safi L et al (2023) Salivary diagnostics in pediatrics and the status of saliva-based biosensors. Biosensors 13:206. https:\/\/doi.org\/10.3390\/bios13020206","journal-title":"Biosensors"},{"key":"7144_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060846","volume":"17","author":"Z Khurshid","year":"2016","unstructured":"Khurshid Z, Zohaib S, Najeeb S et al (2016) Human saliva collection devices for proteomics: an update. Int J Mol Sci 17:846. https:\/\/doi.org\/10.3390\/ijms17060846","journal-title":"Int J Mol Sci"},{"key":"7144_CR11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/bcp.13553","volume":"84","author":"L Hutchinson","year":"2018","unstructured":"Hutchinson L, Sinclair M, Reid B et al (2018) A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants. Br J Clin Pharmacol 84:1089\u20131108. https:\/\/doi.org\/10.1111\/bcp.13553","journal-title":"Br J Clin Pharmacol"},{"key":"7144_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/bdd.2206","volume":"40","author":"MM Alsmadi","year":"2019","unstructured":"Alsmadi MM, Alfarah MQ, Albderat J et al (2019) The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue. Biopharm Drug Dispos 40:325\u2013340. https:\/\/doi.org\/10.1002\/bdd.2206","journal-title":"Biopharm Drug Dispos"},{"key":"7144_CR13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40261-019-00844-y","volume":"39","author":"E Brooks","year":"2019","unstructured":"Brooks E, Tett SE, Isbel NM et al (2019) Investigation of the association between total and free plasma and saliva Mycophenolic Acid concentrations following administration of enteric-coated mycophenolate sodium in adult kidney transplant recipients. Clin Drug Investig 39:1175\u20131184. https:\/\/doi.org\/10.1007\/s40261-019-00844-y","journal-title":"Clin Drug Investig"},{"key":"7144_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jsps.2013.02.002","volume":"22","author":"NM Idkaidek","year":"2014","unstructured":"Idkaidek NM (2014) Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems. Saudi Pharm J 22:79\u201381. https:\/\/doi.org\/10.1016\/j.jsps.2013.02.002","journal-title":"Saudi Pharm J"},{"key":"7144_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1034","volume":"10","author":"A Cati\u0107-\u0110or\u0111evi\u0107","year":"2022","unstructured":"Cati\u0107-\u0110or\u0111evi\u0107 A, Stefanovi\u0107 N, Pavlovi\u0107 I et al (2022) Utility of salivary mycophenolic acid concentration monitoring: modeling and Monte Carlo validation approach. Pharmacol Res Perspect 10:e01034. https:\/\/doi.org\/10.1002\/prp2.1034","journal-title":"Pharmacol Res Perspect"},{"key":"7144_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13121991","volume":"13","author":"M Resztak","year":"2021","unstructured":"Resztak M, Sobiak J, Czyrski A (2021) Recent advances in therapeutic drug monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: a literature review of pediatric studies. Pharmaceutics 13:1991. https:\/\/doi.org\/10.3390\/pharmaceutics13121991","journal-title":"Pharmaceutics"},{"key":"7144_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clinbiochem.2021.11.008","volume":"100","author":"AR Cossart","year":"2022","unstructured":"Cossart AR, Staatz CE, Gorham G, Barraclough KA (2022) Comparison of free plasma versus saliva mycophenolic acid exposure following mycophenolate mofetil administration in adult kidney transplant recipients. Clin Biochem 100:78\u201381. https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.11.008","journal-title":"Clin Biochem"},{"key":"7144_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/01.ftd.0000211826.65607.05","volume":"28","author":"AE Mendonza","year":"2006","unstructured":"Mendonza AE, Gohh RY, Akhlaghi F (2006) Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry. Ther Drug Monit 28:402\u2013406. https:\/\/doi.org\/10.1097\/01.ftd.0000211826.65607.05","journal-title":"Ther Drug Monit"},{"key":"7144_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jpba.2009.05.030","volume":"50","author":"B Shen","year":"2009","unstructured":"Shen B, Li S, Zhang Y et al (2009) Determination of total, free and saliva mycophenolic acid with a LC\u2013MS\/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients. J Pharm Biomed Anal 50:515\u2013521. https:\/\/doi.org\/10.1016\/j.jpba.2009.05.030","journal-title":"J Pharm Biomed Anal"},{"key":"7144_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.chroma.2012.04.008","volume":"1241","author":"MHJ Wiesen","year":"2012","unstructured":"Wiesen MHJ, Farowski F, Feldk\u00f6tter M et al (2012) Liquid chromatography\u2013tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device. J Chromatogr A 1241:52\u201359. https:\/\/doi.org\/10.1016\/j.chroma.2012.04.008","journal-title":"J Chromatogr A"},{"key":"7144_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s43440-024-00574-9","volume":"76","author":"J Sobiak","year":"2024","unstructured":"Sobiak J, Resztak M, Sikora W et al (2024) Liquid chromatography\u2013tandem mass spectrometry method for mycophenolic acid and its glucuronide determination in saliva samples from children with nephrotic syndrome. Pharmacol Rep 76:600\u2013611. https:\/\/doi.org\/10.1007\/s43440-024-00574-9","journal-title":"Pharmacol Rep"},{"key":"7144_CR22","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.7754\/Clin.Lab.2022.211224","volume":"68","author":"A Krahel","year":"2022","unstructured":"Krahel A, Hernik A, Dmitrzak-Weglarz M, Paszynska E (2022) Saliva as diagnostic material and current methods of collection from oral cavity. Clin Lab 68:2072\u20132080. https:\/\/doi.org\/10.7754\/Clin.Lab.2022.211224","journal-title":"Clin Lab"},{"key":"7144_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jchromb.2007.09.036","volume":"859","author":"FA Elbarbry","year":"2007","unstructured":"Elbarbry FA, Shoker AS (2007) Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci 859:276\u2013281. https:\/\/doi.org\/10.1016\/j.jchromb.2007.09.036","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"7144_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/FTD.0b013e3181f01397","volume":"32","author":"B Chen","year":"2010","unstructured":"Chen B, Gu Z, Chen H et al (2010) Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. Ther Drug Monit 32:653\u2013660. https:\/\/doi.org\/10.1097\/FTD.0b013e3181f01397","journal-title":"Ther Drug Monit"},{"key":"7144_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13318-015-0262-9","volume":"41","author":"J Sobiak","year":"2016","unstructured":"Sobiak J, Resztak M, G\u0142yda M et al (2016) Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation. Eur J Drug Metab Pharmacokinet 41:331\u2013338. https:\/\/doi.org\/10.1007\/s13318-015-0262-9","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"7144_CR26","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1021\/mp300250r","volume":"9","author":"N Idkaidek","year":"2012","unstructured":"Idkaidek N, Arafat T (2012) Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. Mol Pharm 9:2358\u20132363. https:\/\/doi.org\/10.1021\/mp300250r","journal-title":"Mol Pharm"},{"key":"7144_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2024.105954","volume":"103","author":"Z Mazidi","year":"2025","unstructured":"Mazidi Z, Wieser M, Spinu N et al (2025) Cyclosporin A toxicity on endothelial cells differentiated from induced pluripotent stem cells: assembling an adverse outcome pathway. Toxicol In Vitro 103:105954. https:\/\/doi.org\/10.1016\/j.tiv.2024.105954","journal-title":"Toxicol In Vitro"},{"key":"7144_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","volume":"78","author":"M Ahlmann","year":"2016","unstructured":"Ahlmann M, Hempel G (2016) The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 78:661\u2013671. https:\/\/doi.org\/10.1007\/s00280-016-3152-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"7144_CR29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2125.2012.04372.x","volume":"75","author":"A Frymoyer","year":"2013","unstructured":"Frymoyer A, Verotta D, Jacobson P, Long-Boyle J (2013) Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol 75:463\u2013475. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04372.x","journal-title":"Br J Clin Pharmacol"},{"key":"7144_CR30","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1128\/AAC.40.8.1935.","volume":"40","author":"CH Koks","year":"1996","unstructured":"Koks CH, Meenhorst PL, Hillebrand MJ et al (1996) Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob Agents Chemother 40:1935\u20131937. https:\/\/doi.org\/10.1128\/AAC.40.8.1935.","journal-title":"Antimicrob Agents Chemother"},{"key":"7144_CR31","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1177\/0091270011422814","volume":"52","author":"H Kim","year":"2012","unstructured":"Kim H, Long-Boyle J, Rydholm N et al (2012) Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. J Clin Pharmacol 52:1665\u20131675. https:\/\/doi.org\/10.1177\/0091270011422814","journal-title":"J Clin Pharmacol"},{"key":"7144_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA et al (2021) Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit 43:150\u2013200. https:\/\/doi.org\/10.1097\/FTD.0000000000000871","journal-title":"Ther Drug Monit"},{"key":"7144_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/01.tp.0000276936.14041.6c","volume":"84","author":"M Naesens","year":"2007","unstructured":"Naesens M, de Loor H, Vanrenterghem Y, Kuypers DRJ (2007) The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-o-glucuronide. Transplantation 84:362\u2013373. https:\/\/doi.org\/10.1097\/01.tp.0000276936.14041.6c","journal-title":"Transplantation"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-07144-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:52:46Z","timestamp":1777902766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-07144-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7144"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-07144-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}